ADAPY Adaptimmune Therapeutics Plc - ADR

$ADAPY Strong approved finish and strong day closing at the highs after 46% rocket yesterday. Continuation tomorrow.

$ADAPY still has about 4 irons in fire besides that which was in part divested IP Wise. For those who baulk at $0.20-30: like cases in Biotech and even one internal historical case support the perspective that $0.55-$1/ADS is at butt end for reasonably lower value case BO. As points out, comparable cases in biotech BO have ingested far less mature or less promising IP than ADAPY for $Bn's. A high premium BO case for this portfolio is actually multiples higher than $1/ADS. Nay Sayers are not without their own thoughts, but there is more to see here than can be said in a few words on those merits. In short ADAPY retains a lot of potential!

$ADAPY their research helped bring the first engineered T-cell therapy for a solid tumor to patients. With PRAME- and CD70-directed programs and an allogeneic platform in its next chapter, there’s real scientific potential, and upside here, whether that development moves forward independently or with partners.

$ADAPY I have previously mentioned multiple times that the lete-cel BLA may already have been filed months ago and it may be in regulatory review, because of from LI, "Led Pre-Approval Inspection (PAI) readiness for US and UK clinical sites supporting the lete-cel BLA submission — both sites received No Action Indicated (NAI), the highest possible FDA and MHRA regulatory outcome." The PAI is done at the final stages of regulatory review and they received NAI. The only argument speaking against this is that person is mentioning a 'mock' FDA and MHRA simulation in-house meaning the sites go through an audit of how an FDA and MHRA would really look like. Assuming it has been filed, I was thinking the rise of market cap this week ~4 million could be a reflection of MS payments for lete-cel. In any event, once lete-cel is approved likely in Q1, 2027 or with delays in Q2 an additional 10 million is guaranteed.

$ADAPY ESMO is on October 23rd in Madrid there is tons about cell therapy if you looked into the abstracts.

$ADAPY Some may feel that I'm over imagining elaborate editing additions "knock-ins" into the hiPSC chassis but out of their own mouths they proclaimed "we will combine this platform with EVERYTHING" so this obviously includes PRAME: Also if you read further they were planning to submit an IND testifies to how advanced the architecture is:

$ADAPY may trade like a penny stock on the OTC, but will sell like an auctioned Cadillac.

$ADAPY Connecting the dots it looks like immatics is the mystery buyer of OUR PRAME.. We're rising to the surface of that deal since that version of PRAME was part of an entire catalog of autologous derived assets we've existed! Furthermore, we still own rights to exploit an allogeneic derived, hiPSC edited PRAME via uza cel in PROC. Where immatics currently stands with their PRAME:

$ADAPY Cont'd from last post: PRAME's expressed HIGHLY in Melanoma so this is undoubtedly the target for CCTI (TILs have outstanding success) Why would adapy "retain" IP rights with TILs? Because they will continue to work with PRAME

$ADAPY biotech reverse mergers up to 36 so far this year compared to 4 last year. Published yesterday

$ADAPY Thanks to all of you technical wizards...I've learn more on message boards than four years of college about the drug development/regulatory processes. I appreciate mgmt for not panicking and sell the company short despite the pressures from shareholders. I've maintained that mgmts are working diligently to increase value and time may prove that. The naysayers believe that every biotech will be a winner..investing is a balance of risk/reward and we're in a sector thats the epitome of that. Pioneering biotechs have significant hidden value..as our more esteemed posters have noted. Sometimes, the processes from start to finish is more valuable than the drug itself...and it seems that our adapy has some elements of that. We may be sitting on something much more valuable than any realize...if so, mgmt deserve some kudos for seeing it through, taking their time, getting every penny for SH...thats the hallmarks of good mgmt. I enjoy the technical read guys.

$ADAPY not only did we break out Wednesday but more importantly we gave none if it back. Primed for continuation next week 👍🏼

$ADAPY average just over$3. I'll wait for $30 or sell at $4 lol 💪🏼 Stonky bought in the 14s hahaha moron

$ADAPY let’s all face the facts here we are in tight trading range until a partnership or BO. Doesn’t matter what the market does or the bio sector. Case closed That is my opinion from what I see.

$ADAPY nice to see a bunch of 100k share blocks going through. Biggest volume we’ve seen in a couple weeks

$ADAPY ADP TIL IL7, broad trials charted across 6 phases countries all across EU targeting severe melanoma according to dashboard = multiple irons in a single fire. + Multiple fires & additional irons in each across the broader but strategically stacking and interrelated remaining IP, also increases applicability of two other IP pipelines as has shared. Many possibilities using combination math, points to increasing value across the entire IP stack.

$ADAPY bid to ask is a 95% gap at close (~50% from the actual close price), a nearly 250,000 share block going through today. We’re there…

$ADAPY This is an event-driven stock, where its price is likely only primarily to be influenced by the possibility of a catalyst or major news event, rather than by ordinary day-to-day trading. Given the thin trading and wide spreads, normal price-discovery assumptions simply cannot reliably apply on most days.

$ADAPY aretard pipper must be pleased IOVA is down another 10% today. In aretard world, you buy high and sell low. The lower the better!!!

$ADAPY ask at .04 to start the day. Let’s goo! I don’t pay attention to these naysayers. Looking for .17-.35 on this.